New Paradigms in HR-Positive Advanced Breast Cancer

Topics for Discussion

First-Line PALOMA-2 Trial*: PFS Results

First-Line MONALEESA-2 Trial*: PFS

Subgroup Analysis of PFS: PALOMA-2

Deciding When to Use CDK4/6 Inhibitors in First-Line Setting

ESMO Magnitude of Clinical Benefit Scale

Increased QoL With Palbociclib Plus Fulvestrant In Previously Treated HR-Positive, HER2-Negative MBC

Second-Line PALOMA-3 Trial*: PFS

CDK4/6 Inhibitors: Tolerability

CDK4/6 Inhibitors: Incidence of Neutropenia

Recommended Palbociclib Dose Adjustments for Patients With Neutropenia

Novel Targets for Hormone Therapy in Breast Cancer

When Should CDK4/6 Inhibitors Be Used in Second-Line Setting?

Addition of Everolimus to Exemestane for Second-Line Treatment: BOLERO-2* PFS Analysis

PALOMA-3*: Postprogression Therapies

CDK4/6 Inhibitors: Biomarkers of Response and Resistance

CDK4/6 Inhibitors: Biomarkers of Response and Resistance (cont)

Availability of CDK4/6 Inhibitors for Treatment of HR-Positive, HER2-Negative MBC

Abbreviations

Abbreviations (cont)